The Impact Of An AIDS Vaccine In Developing Countries: A New Model And Initial Results

Abstract

A new model was developed to examine the potential impacts of an AIDS vaccine in developing countries. The findings suggest that even a modestly efficacious firstgeneration vaccine could have a profound effect on the AIDS pandemic. A vaccine with 50 percent efficacy provided to 30 percent of the population would reduce new annual infections by 34 percent (seventeen million infections avoided) over fifteen years and result in substantial financial savings. A more efficacious vaccine, combined with expanded delivery, would do even more to control the pandemic. It therefore makes sense to continue investing in AIDS vaccine research and development and the eventual manufacture and widespread distribution of a vaccine. [Health Affairs 26, no. 4 (2007):

Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA

“…Nonetheless, only about half of the viruses and pseudoviruses tested were neutralized by the sera induced by the best of the immunizing regimens. While even a modestly efficacious first-generation vaccine could have a profound effect on the AIDS epidemic (62), to achieve more complete coverage, Abs to additional epitopes will need to be induced. Existing data suggest that Abs to many Env epitopes, including V3, will work additively to provide that breadth (55,68,74).…”

Social and Behavioral Challenges of HIV Vaccines: Implications for Social Work and Social Science

“…For example, many of us expect that a vaccine is equivalent with complete protection against a disease. However, it seems likely that initial HIV vaccines may be only partially efficacious (Stover, Bollinger, Hecht, Williams, & Roca, 2007). Even a low to moderate efficacy vaccine could prevent millions of new HIV infections worldwide (Stover et al, 2007); however, if people are loathe to accept innoculation with a 50% efficacy vaccine, then such a vaccine will not be effective on a population level.…”

What impact would an HIV/AIDS vaccine have on the HIV/AIDS epidemic in Kenya?

“…The International AIDS Vaccine Initiative (IAVI) and the Futures Institute have worked together to develop a mathematical model to study the potential impacts of an HIV vaccine on the pandemic both globally [4], and in countries such as Kenya, China, Uganda and Brazil [5]. In Kenya, IAVI developed this research in collaboration with the Kenya HIV and AIDS Research Coordinating Mechanism (KARSCOM) and a team of researchers at the Kenya AIDS Vaccine Initiative (KAVI) led the technical work with assistance from the Futures Institute.…”